Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Legend Starts Submission for US Approval of BCMA CAR-T Therapy

publication date: Dec 21, 2020

Legend Bio started a rolling submission of a Biologics License Application for US approval of its BCMA CAR-T therapy. Ciltacabtagene autoleucel (cilta-cel) is indicated for adults with relapsed and/or refractory multiple myeloma. In late 2017, Legend out-licensed rights for the candidate to Janssen Pharma, a division of Johnson & Johnson, in a deal worth $350 million upfront with more than $1 billion available in milestones. The BLA filing triggered a $75 million payment to Legend. More details....

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.